The Valley Desk

NCT03696212 · Interventional trial

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Overall registry status Terminated

Phase 1 · Phase 2

Conditions Non-small Cell Lung Cancer Adenocarcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov